On September 6, 2017 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will highlight data on sitravatinib at the IASLC 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan (learn more at www.iaslc.org) (Press release, Mirati, SEP 6, 2017, View Source [SID1234520399]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy
Oral Presentation Session: MA 02 – Emerging Targets; Mini Oral
Presentation Topic: 04. Clinical Design, Statistics and Clinical Trials
Location: Room 511 + 512
Date and Time: October 16, 11:00 — 12:30 JST
Abstract ID: 9720
Presenter: Ticiana A. Leal, M.D.

Title: CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib
Poster Session: P3.01 – Poster Session with Presenters Present
Poster Topic: 01. Advanced NSCLC
Location: Exhibit Hall, Hall B+C
Abstract ID: 9560
Presentation Date and Time: October 18, 9:30 — 16:00 JST
Presenter: Lyudmila A. Bazhenova. M.D.